Charles N. York II - 15 Feb 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
COO, CFO and Secretary
Signature
/s/ Charles N. York II
Issuer symbol
DAWN
Transactions as of
15 Feb 2023
Net transactions value
-$18,203
Form type
4
Filing time
17 Feb 2023, 16:35:15 UTC
Previous filing
23 Jan 2023
Next filing
21 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +1,375 +0.51% 270,185 15 Feb 2023 Direct F1
transaction DAWN Common Stock Options Exercise +2,250 +0.83% 272,435 15 Feb 2023 Direct F1
transaction DAWN Common Stock Sale $18,203 -930 -0.34% $19.57 271,505 16 Feb 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -1,375 -8.3% $0.000000 15,125 15 Feb 2023 Common Stock 1,375 Direct F1, F3
transaction DAWN Restricted Stock Units Options Exercise $0 -2,250 -6.2% $0.000000 33,750 15 Feb 2023 Common Stock 2,250 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.